论文部分内容阅读
CD137 (4-1BB),a member of the TNF receptor superfamily,is an inducible T cell costimulatory receptorprimarily expressed on activated CD4~+ and CD8~+ T cells.Agonistic monoclonal antibodies (mAbs) against CD137greatly enhance T cell-mediated immune responses against many types of tumors and viruses.Surprisingly,theseagonists also showed therapeutic effects in several autoimmune diseases.These findings suggest that in differentdisease environments,CD137 engagement with agonist mAb in vivo can diametrically modulate immuneresponse outcomes.Therefore,CD137 agonists represent a promising immunotherapeutic approach to a widearray of disparate immune disorders.However,CD137’s potency in modulating immune response necessitatescaution when targeting CD137 clinically.Cellular & Molecular Immunology.2004;1(1):31-36.
A member of the TNF receptor superfamily, is an inducible T cell costimulatory receptor primed by activated CD4 ~ + and CD8 ~ + T cells. Agonistic monoclonal antibodies (mAbs) against CD137glyly enhance T cell-mediated immune responses against many types of tumors and viruses. Surprisingly, theseagonists also showed therapeutic effects in several autoimmune diseases. Thesese findings suggest that in differentdisease environments, CD137 engagement with agonist mAb in vivo cans diametrically modulate immuneresponse outcomes. Beforefore, CD137 agonists represent a promising immunotherapeutic approach To a wide array of disparate immune disorders. However, CD137’s potency in modulating immune response necessitatction when targeting CD137 clinically. Cellular & Molecular Immunology. 2004; 1 (1): 31-36.